Databases applicable to quantitative hazard/risk assessment-Towards a predictive systems toxicology

Toxicology and Applied Pharmacology

Volumn 233, Issue 1, 2008, Pages 34-44

  Waters, Michael ^a   Jackson, Marcus ^a  

^a ILS Inc   (United States)

Author keywords

Carcinogenicity; Data integration; Genotoxicity; Mode of action; Predictive toxicology; Toxicogenomics

Indexed keywords

CARCINOGEN; MUTAGENIC AGENT; TOXIC SUBSTANCE;

ARTICLE; CARCINOGENICITY; DANGEROUS GOODS; DATA BASE; GENOTOXICITY; HAZARD ASSESSMENT; HUMAN; NONHUMAN; PEER REVIEW; PREDICTION; PUBLICATION; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; TOXICOGENETICS;

ANIMALS; DATABASES, FACTUAL; EVALUATION STUDIES AS TOPIC; FORECASTING; HAZARDOUS SUBSTANCES; HUMANS; INFORMATION SYSTEMS; RISK ASSESSMENT; UNITED STATES; UNITED STATES ENVIRONMENTAL PROTECTION AGENCY;

RODENTIA;

EID: 55749113514     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2007.12.036     Document Type: Article

References (58)

1. Anna C.H., Iida M., Sills R.C., and Devereux T.R. Expression of potential beta-catenin targets, cyclin D1, c-Jun, c-Myc, E-cadherin, and EGFR in chemically induced hepatocellular neoplasms from B6C3F1 mice. Toxicol. Appl. Pharmacol. 190 (2003) 135-145
2. Barnas C., Martel-Planche G., Furukawa Y., Hollstein M., Montesano R., and Hainaut P. Inactivation of the p53 protein in cell lines derived from human esophageal cancers. Int. J. Cancer 71 (1997) 79-87
3. Behrens J. Cadherins and catenins: role in signal transduction and tumor progression. Cancer Metastasis Rev. 18 (1999) 15-30
4. Blum C.A., Tanaka T., Zhong X., Li Q., Dashwood W.M., Pereira C., Xu M., and Dashwood R.H. Mutational analysis of Ctnnb1 and Apc in tumors from rats given 1,2-dimethylhydrazine or 2-amino-3-methylimidazo[4,5-f]quinoline: mutational 'hotspots' and the relative expression of beta-catenin and c-jun. Mol. Carcinog. 36 (2003) 195-203
5. Bolt A.B., Papanikolaou A., Delker D.A., Wang Q.S., and Rosenberg D.W. Azoxymethane induces KI-ras activation in the tumor resistant AKR/J mouse colon. Mol. Carcinog. 27 (2000) 210-218
6. Fearon E.R., and Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61 (1990) 759-767
7. Fearon E.R., Hamilton S.R., and Vogelstein B. Clonal analysis of human colorectal tumors. Science 238 (1987) 193-197
8. Gimenez-Conti I.B., Collet A.M., Lanfranchi H., Itoiz M.E., Luna M., Xu H.J., Hu S.X., Benedict W.F., and Conti C.J. p53, Rb, and cyclin D1 expression in human oral verrucous carcinomas. Cancer 78 (1996) 17-23
9. Harris A.L. p53 expression in human breast cancer. Adv. Cancer Res. 59 (1992) 69-88
10. Jackson M.A., Stack H.F., and Waters M.D. Activity profiles of carcinogenicity data: application in hazard identification and risk assessment. Mutat. Res. 394 (1997) 113-124
11. Jackson P.E., Cooper D.P., O'Connor P.J., and Povey A.C. The relationship between 1,2-dimethylhydrazine dose and the induction of colon tumours: tumour development in female SWR mice does not require a K-ras mutational event. Carcinogenesis 20 (1999) 509-513
12. Jackson M.A., Lea I., Rashid A., Peddada S.D., and Dunnick J.K. Genetic alterations in cancer knowledge system: analysis of gene mutations in mouse and human liver and lung tumors. Toxicol. Sci. 90 (2006) 400-418
13. Kanamoto R., Azuma N., Tsuchihashi Y., Suda H., Saeki T., and Iwami K. Non-involvement of the K-ras mutation in colon carcinogenesis promoted by dietary deoxycholate in azoxymethane-treated rats. Biosci. Biotechnol. Biochem. 65 (2001) 848-852
14. Kavlock R.J., Greene J.A., Kimmel G.L., Morrissey R.E., Owens E., Rogers J.M., Sadler T.W., Stack H.F., Waters M.D., and Welsch F. Activity profiles of developmental toxicity: design considerations and pilot implementation. Teratology 43 (1991) 159-185
15. Kinjo T., Suzui M., Morioka T., Inamine M., Kaneshiro T., Arakaki J., Chiba I., Sunagawa N., Nishimaki T., and Yoshimi N. Reduced expression level of mgmt mRNA and beta-catenin gene mutation in rat colon tumors. Anticancer Res. 26 (2006) 2829-2832
16. Knudson A.G. Antioncogenes and human cancer. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 10914-10921
17. Kohno H., Suzuki R., Sugie S., and Tanaka T. Beta-catenin mutations in a mouse model of inflammation-related colon carcinogenesis induced by 1,2-dimethylhydrazine and dextran sodium sulfate. Cancer Sci. 96 (2005) 69-76
18. Levine A.J., Chang A., Dittmer D., Notterman D.A., Silver A., Thorn K., Welsh D., and Wu M. The p53 tumor suppressor gene. J. Lab. Clin. Med. 123 (1994) 817-823
19. Luceri C., De Filippo C., Caderni G., Gambacciani L., Salvadori M., Giannini A., and Dolara P. Detection of somatic DNA alterations in azoxymethane-induced F344 rat colon tumors by random amplified polymorphic DNA analysis. Carcinogenesis 21 (2000) 1753-1756
20. Maronpot R.R., Giles H.D., Dykes D.J., and Irwin R.D. Furan-induced hepatic cholangiocarcinomas in Fischer 344 rats. Toxicol. Pathol. 19 (1991) 561-570
21. Mirabelli-Primdahl L., Gryfe R., Kim H., Millar A., Luceri C., Dale D., Holowaty E., Bapat B., Gallinger S., and Redston M. Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. Cancer Res. 59 (1999) 3346-3351
22. Nakayama K., Kawano Y., Kawakami Y., Moriwaki N., Sekijima M., Otsuka M., Yakabe Y., Miyaura H., Saito K., Sumida K., and Shirai T. Differences in gene expression profiles in the liver between carcinogenic and non-carcinogenic isomers of compounds given to rats in a 28-day repeat-dose toxicity study. Toxicol. Appl. Pharmacol. 217 (2006) 299-307
23. Nambiar P.R., Giardina C., Guda K., Aizu W., Raja R., and Rosenberg D.W. Role of the alternating reading frame (P19)-p53 pathway in an in vivo murine colon tumor model. Cancer Res. 62 (2002) 3667-3674
24. Nie A.Y., McMillian M., Parker J.B., Leone A., Bryant S., Yieh L., Bittner A., Nelson J., Carmen A., Wan J., and Lord P.G. Predictive toxicogenomics approaches reveal underlying molecular mechanisms of nongenotoxic carcinogenicity. Mol. Carcinog. 45 (2006) 914-933
25. Okamoto M., Ohtsu H., Kominami R., and Yonekawa H. Mutational and LOH analyses of p53 alleles in colon tumors induced by 1,2-dimethylhydrazine in F1 hybrid mice. Carcinogenesis 16 (1995) 2659-2666
26. Ray V.A., Kier L.D., Kannan K.L., Haas R.T., Auletta A.E., Wassom J.S., Nesnow S., and Waters M.D. An approach to identifying specialized batteries of bioassays for specific classes of chemicals: class analysis using mutagenicity and carcinogenicity relationships and phylogenetic concordance and discordance patterns. 1. Composition and analysis of the overall data base. A report of phase II of the U.S. Environmental Protection Agency Gene-Tox Program. Mutat. Res. 185 (1987) 197-241
27. Ruepp S., Boess F., Suter L., de Vera M.C., Steiner G., Steele T., Weiser T., and Albertini S. Assessment of hepatotoxic liabilities by transcript profiling. Toxicol. Appl. Pharmacol. 207 (2005) 161-170
28. Shivapurkar N., Tang Z., Ferreira A., Nasim S., Garett C., and Alabaster O. Sequential analysis of K-ras mutations in aberrant crypt foci and colonic tumors induced by azoxymethane in Fischer-344 rats on high-risk diet. Carcinogenesis 15 (1994) 775-778
29. Shivapurkar N., Belinsky S.A., Wolf D.C., Tang Z., and Alabaster O. Absence of p53 gene mutations in rat colon carcinomas induced by azoxymethane. Cancer Lett. 96 (1995) 63-70
30. Sills R.C., Boorman G.A., Neal J.E., Hong H.L., and Devereux T.R. Mutations in ras genes in experimental tumours of rodents. IARC Sci. Publ. (1999) 55-86
31. Sills R.C., Hong H.L., Flake G., Moomaw C., Clayton N., Boorman G.A., Dunnick J., and Devereux T.R. o-Nitrotoluene-induced large intestinal tumors in B6C3F1 mice model human colon cancer in their molecular pathogenesis. Carcinogenesis 25 (2004) 605-612
32. Sparks A.B., Morin P.J., Vogelstein B., and Kinzler K.W. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res. 58 (1998) 1130-1134
33. Steiner G., Suter L., Boess F., Gasser R., de Vera M.C., Albertini S., and Ruepp S. Discriminating different classes of toxicants by transcript profiling. Environ. Health Perspect. 112 (2004) 1236-1248
34. Suzui M., Ushijima T., Dashwood R.H., Yoshimi N., Sugimura T., Mori H., and Nagao M. Frequent mutations of the rat beta-catenin gene in colon cancers induced by methylazoxymethanol acetate plus 1-hydroxyanthraquinone. Mol. Carcinog. 24 (1999) 232-237
35. Suzui M., Sugie S., Mori H., Okuno M., Tanaka T., and Moriwaki H. Different mutation status of the beta-catenin gene in carcinogen-induced colon, brain, and oral tumors in rats. Mol. Carcinog. 32 (2001) 206-212
36. Suzui M., Okuno M., Tanaka T., Nakagama H., and Moriwaki H. Enhanced colon carcinogenesis induced by azoxymethane in min mice occurs via a mechanism independent of beta-catenin mutation. Cancer Lett. 183 (2002) 31-41
37. Takahashi M., and Wakabayashi K. Gene mutations and altered gene expression in azoxymethane-induced colon carcinogenesis in rodents. Cancer Sci. 95 (2004) 475-480
38. Takahashi M., Fukuda K., Sugimura T., and Wakabayashi K. Beta-catenin is frequently mutated and demonstrates altered cellular location in azoxymethane-induced rat colon tumors. Cancer Res. 58 (1998) 42-46
39. Takahashi M., Mutoh M., Kawamori T., Sugimura T., and Wakabayashi K. Altered expression of beta-catenin, inducible nitric oxide synthase and cyclooxygenase-2 in azoxymethane-induced rat colon carcinogenesis. Carcinogenesis 21 (2000) 1319-1327
40. Takahashi M., Nakatsugi S., Sugimura T., and Wakabayashi K. Frequent mutations of the beta-catenin gene in mouse colon tumors induced by azoxymethane. Carcinogenesis 21 (2000) 1117-1120
41. Thomas R.S., Pluta L., Yang L., and Halsey T.A. Application of genomic biomarkers to predict increased lung tumor incidence in 2-year rodent cancer bioassays. Toxicol. Sci. 97 (2007) 55-64
42. Trukhanova L.S., Hong H.H., Sills R.C., Bowser A.D., Gaul B., Boorman G.A., Turusov V.S., Devereux T.R., and Dixon D. Predominant p53 G->A transition mutation and enhanced cell proliferation in uterine sarcomas of CBA mice treated with 1,2-dimethylhydrazine. Toxicol. Pathol. 26 (1998) 367-374
43. Tsujimura K., Asamoto M., Suzuki S., Hokaiwado N., Ogawa K., and Shirai T. Prediction of carcinogenic potential by a toxicogenomic approach using rat hepatoma cells. Cancer Sci. 97 (2006) 1002-1010
44. Vogelstein B., and Kinzler K.W. The multistep nature of cancer. Trends Genet. 9 (1993) 138-141
45. Vogelstein B., Fearon E.R., Hamilton S.R., Kern S.E., Preisinger A.C., Leppert M., Nakamura Y., White R., Smits A.M., and Bos J.L. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 319 (1988) 525-532
46. Vogelstein B., Fearon E.R., Kern S.E., Hamilton S.R., Preisinger A.C., Nakamura Y., and White R. Allelotype of colorectal carcinomas. Science 244 (1989) 207-211
47. Wali R.K., Skarosi S., Hart J., Zhang Y., Dolan M.E., Moschel R.C., Nguyen L., Mustafi R., Brasitus T.A., and Bissonnette M. Inhibition of O(6)-methylguanine-DNA methyltransferase increases azoxymethane-induced colonic tumors in rats. Carcinogenesis 20 (1999) 2355-2360
48. Waters M.D. Development and impact of the Gene-Tox-Program, genetic activity profiles, and their computerized data bases. Environ. Mol. Mutagen 23 Suppl 24 (1994) 67-72
49. Waters M.D., and Auletta A. The GENE-TOX program: genetic activity evaluation. J. Chem. Inf. Comput. Sci. 21 (1981) 35-38
50. Waters M.D., and Fostel J.M. Toxicogenomics and systems toxicology: aims and prospects. Nat. Rev. Genet. 5 (2004) 936-948
51. Waters M.D., Stack H.F., Brady A.L., Lohman P.H., Haroun L., and Vainio H. Use of computerized data listings and activity profiles of genetic and related effects in the review of 195 compounds. Mutat. Res. 205 (1988) 295-312
52. Waters M.D., Stack H.F., Garrett N.E., and Jackson M.A. The Genetic Activity Profile database. Environ. Health Perspect. 96 (1991) 41-45
53. Waters M.D., Stack H.F., and Jackson M.A. Genetic toxicology data in the evaluation of potential human environmental carcinogens. Mutat. Res. 437 (1999) 21-49
54. Waters M., Boorman G., Bushel P., Cunningham M., Irwin R., Merrick A., Olden K., Paules R., Selkirk J., Stasiewicz S., Weis B., Van Houten B., Walker N., and Tennant R. Systems toxicology and the Chemical Effects in Biological Systems (CEBS) knowledge base. EHP Toxicogenomics 111 (2003) 15-28
55. Waters M.D., Boorman G., Bushel P., Cunningham M., Irwin R., Merrick A., Olden K., Paules R., Selkirk J., Stasiewicz S., Weis B., Van Houten B., Walker N., and Tennant R. Systems toxicology and the chemical effects in biological systems knowledge base. Environment. Health Perspect. 111 (2003) 811-824
56. Waters M., Stasiewicz S., Merrick B.A., Tomer K., Bushel P., Paules R., Stegman N., Nehls G., Yost K.J., Johnson C.H., Gustafson S.F., Xirasagar S., Xiao N., Huang C.C., Boyer P., Chan D.D., Pan Q., Gong H., Taylor J., Choi D., Rashid A., Ahmed A., Howle R., Selkirk J., Tennant R., and Fostel J. CEBS Chemical Effects in Biological Systems: a public data repository integrating study design and toxicity data with microarray and proteomics data. Nucleic Acids R. (2007)
57. Yamada Y., Oyama T., Hirose Y., Hara A., Sugie S., Yoshida K., Yoshimi N., and Mori H. beta-Catenin mutation is selected during malignant transformation in colon carcinogenesis. Carcinogenesis 24 (2003) 91-97
58. Zambetti G.P., and Levine A.J. A comparison of the biological activities of wild-type and mutant p53. Faseb. J. 7 (1993) 855-865